Berezin AE. Predictive value of the systemic immune inflammation index in recurrence of atrial fibrillation after radiofrequency catheter ablation. World J Cardiol 2025; 17(1): 102981 [PMID: 39866209 DOI: 10.4330/wjc.v17.i1.102981]
Corresponding Author of This Article
Alexander E Berezin, MD, PhD, Professor, Department of Internal Medicine-II, Paracelsus Medical University Salzburg, Strubergasse 21, Salzburg 5020, Austria. aeberezin@gmail.com
Research Domain of This Article
Medicine, General & Internal
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Cardiol. Jan 26, 2025; 17(1): 102981 Published online Jan 26, 2025. doi: 10.4330/wjc.v17.i1.102981
Predictive value of the systemic immune inflammation index in recurrence of atrial fibrillation after radiofrequency catheter ablation
Alexander E Berezin
Alexander E Berezin, Department of Internal Medicine-II, Paracelsus Medical University Salzburg, Salzburg 5020, Austria
Author contributions: Berezin AE was the sole author for this manuscript; the author read and approved the final version of the manuscript to be published.
Conflict-of-interest statement: The author declares no conflict of interest in publishing the manuscript.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Alexander E Berezin, MD, PhD, Professor, Department of Internal Medicine-II, Paracelsus Medical University Salzburg, Strubergasse 21, Salzburg 5020, Austria. aeberezin@gmail.com
Received: November 5, 2024 Revised: December 21, 2024 Accepted: January 2, 2025 Published online: January 26, 2025 Processing time: 78 Days and 16 Hours
Abstract
The recurrence of atrial fibrillation (AF) in patients after successful radiofrequency catheter ablation (RFCA) appears to be an unresolved clinical issue and needs to be clearly elucidated. There are many factors associated with AF recurrence, such as duration of AF, male sex, concomitant heart failure, hemodynamic parameters, chronic obstructive pulmonary disease, hypertension, obstructive sleep apnea, hyperthyroidism, smoking and obesity. However, the inflammatory changes are strongly associated with electrical and structural cardiac remodeling, cardiac damage, myocardial fibrotic changes, microvascular dysfunction and altered reparative response. In this context, biomarkers reflecting the different stages of AF pathogenesis deserve thorough investigation. The authors of the retrospective study revealed that one-year recurrence rate of non-valvular AF in the high systemic immune inflammation (SII) index group was significantly increased compared to that of the low SII index group and provided additional predictive value to the APPLE. Furthermore, the authors suggest that this biomarker may help physicians to optimize the selection of AF patients and to develop a personalized treatment approach. In conclusion, the SII index may serve as a valuable indicator of recurrent AF in patients after RFCA and may be a biomarker with plausible predictive value for poor clinical outcomes.
Core Tip: Elevated systemic immuno-inflammatory index appears to be a strong indicator of recurrent atrial fibrillation in patients after effective radiofrequency catheter ablation and may serve as a biomarker with plausible predictive value for poor clinical outcomes.
